BACKGROUND:Major depressive disorder (MDD) frequently co-occurs in adolescents with substance use disorders (SUDs) and attention deficit hyperactivity disorder (ADHD), but the impact of MDD on substance treatment and ADHD outcomes and implications for clinical practice are unclear. METHODS: Adolescents (n=303; ages 13-18) meeting DSM-IV criteria for ADHD and SUD were randomized to osmotic release methylphenidate (OROS-MPH) or placebo and 16 weeks of cognitive behavioral therapy (CBT). Adolescents with (n=38) and without (n=265) MDD were compared on baseline demographic and clinical characteristics as well as non-nicotine substance use and ADHD treatment outcomes. RESULTS:Adolescents with MDD reported more non-nicotine substance use days at baseline and continued using more throughout treatment compared to those without MDD (p<0.0001 based on timeline followback; p<0.001 based on urine drug screens). There was no difference between adolescents with and without MDD in retention or CBT sessions attended. ADHD symptom severity (based on DSM-IV ADHD rating scale) followed a slightly different course of improvement although with no difference between groups in baseline or 16-week symptom severity or 16-week symptom reduction. There was no difference in days of substance use or ADHD symptom outcomes over time in adolescents with MDD or those without MDD treated with OROS-MPH or placebo. Depressed adolescents were more often female, older, and not court ordered. CONCLUSIONS: These preliminary findings suggest that compared to non-depressed adolescents with ADHD and SUD, those with co-occurring MDD have more severe substance use at baseline and throughout treatment. Such youth may require interventions targeting depression.
RCT Entities:
BACKGROUND: Major depressive disorder (MDD) frequently co-occurs in adolescents with substance use disorders (SUDs) and attention deficit hyperactivity disorder (ADHD), but the impact of MDD on substance treatment and ADHD outcomes and implications for clinical practice are unclear. METHODS: Adolescents (n=303; ages 13-18) meeting DSM-IV criteria for ADHD and SUD were randomized to osmotic release methylphenidate (OROS-MPH) or placebo and 16 weeks of cognitive behavioral therapy (CBT). Adolescents with (n=38) and without (n=265) MDD were compared on baseline demographic and clinical characteristics as well as non-nicotine substance use and ADHD treatment outcomes. RESULTS: Adolescents with MDD reported more non-nicotine substance use days at baseline and continued using more throughout treatment compared to those without MDD (p<0.0001 based on timeline followback; p<0.001 based on urine drug screens). There was no difference between adolescents with and without MDD in retention or CBT sessions attended. ADHD symptom severity (based on DSM-IV ADHD rating scale) followed a slightly different course of improvement although with no difference between groups in baseline or 16-week symptom severity or 16-week symptom reduction. There was no difference in days of substance use or ADHD symptom outcomes over time in adolescents with MDD or those without MDD treated with OROS-MPH or placebo. Depressed adolescents were more often female, older, and not court ordered. CONCLUSIONS: These preliminary findings suggest that compared to non-depressed adolescents with ADHD and SUD, those with co-occurring MDD have more severe substance use at baseline and throughout treatment. Such youth may require interventions targeting depression.
Authors: Christopher J Kratochvil; Jeffrey H Newcorn; L Eugene Arnold; David Duesenberg; Graham J Emslie; Humberto Quintana; Elias H Sarkis; Karen Dineen Wagner; Haitao Gao; David Michelson; Joseph Biederman Journal: J Am Acad Child Adolesc Psychiatry Date: 2005-09 Impact factor: 8.829
Authors: E A Whitmore; S K Mikulich; L L Thompson; P D Riggs; G A Aarons; T J Crowley Journal: Drug Alcohol Depend Date: 1997-08-25 Impact factor: 4.492
Authors: Kathryn D Baker; Dan I Lubman; Elizabeth M Cosgrave; Eoin J Killackey; Hok Pan Yuen; Leanne Hides; Gennady N Baksheev; Joe A Buckby; Alison R Yung Journal: Aust N Z J Psychiatry Date: 2007-11 Impact factor: 5.744
Authors: Lokesh Guglani; Suzanne L Havstad; Christine Cole Johnson; Dennis R Ownby; Christine L M Joseph Journal: Ann Allergy Asthma Immunol Date: 2012-08-15 Impact factor: 6.347
Authors: Andrea L Howard; Traci M Kennedy; Erin P Macdonald; John T Mitchell; Margaret H Sibley; Arunima Roy; L Eugene Arnold; Jeffery N Epstein; Stephen P Hinshaw; Betsy Hoza; Annamarie Stehli; James M Swanson; Brooke S G Molina Journal: J Abnorm Child Psychol Date: 2019-12
Authors: Michael C Meinzer; Peter M Lewinsohn; Jeremy W Pettit; John R Seeley; Jeff M Gau; Andrea Chronis-Tuscano; James G Waxmonsky Journal: Depress Anxiety Date: 2013-02-19 Impact factor: 6.505
Authors: Ole Jakob Storebø; Erica Ramstad; Helle B Krogh; Trine Danvad Nilausen; Maria Skoog; Mathilde Holmskov; Susanne Rosendal; Camilla Groth; Frederik L Magnusson; Carlos R Moreira-Maia; Donna Gillies; Kirsten Buch Rasmussen; Dorothy Gauci; Morris Zwi; Richard Kirubakaran; Bente Forsbøl; Erik Simonsen; Christian Gluud Journal: Cochrane Database Syst Rev Date: 2015-11-25